Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Metalloendopeptidases
  • Neoplasms
  • Organic Chemicals

abstract

  • The recommended dose of BAY 12-9566 for subsequent disease directed studies is 800 mg twice daily, which resulted in biologically relevant plasma C(ss) values and an acceptable toxicity profile. Although exploratory studies of MMPs in plasma were not revealing, it is conceivable that some tumor types and disease settings are more likely to produce more readily quantifiable levels of activated MMPs than others. Therefore, attempts to identify and quantify surrogate markers of MMP inhibitory effects should continue to be performed in disease-directed studies in more homogenous patient populations.

publication date

  • January 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10623708

Additional Document Info

start page

  • 178

end page

  • 86

volume

  • 18

number

  • 1